Pathological Effects of Drugs on the Lung

  • B. Corrin
Part of the Ettore Majorana International Science Series book series (EMISS, volume 14)

Abstract

It is estimated that 5% of all hospital admissions are due to drugs, that 10–18% of inpatients experience a drug reaction and that 3% of hospital deaths may be drug related (1,2). The lungs are often involved in these adverse reactions. Hutchinson et al (3) have described a potentially useful scheme for the operational assessment of whether or not a particular clinical manifestation represents an adverse drug reaction. This considers previous experience with the drug, alternative etiological candidates, the timing of events, drug levels, the effect of withdrawing the drug and rechallenge with the drug. The mechanism of a drug reaction may be based on overdosage, intolerence, a side ef f ect, a secondary ef f ect, hypersensitivity or idiosyncrasy (4). Drug reactions may be further classified according to the type of drug (analgesic, antibiotic, chemo-therapeutic agent, hormone, vasoactive agent, etc) or the pattern of disease. The last method is adopted here. Drugs may cause the following adverse pulmonary reactions:
  1. (1)

    Central depression of respiration

     
  2. (2)

    Broncho-constriction

     

Keywords

Primary Pulmonary Hypertension Diffuse Alveolar Damage Foreign Body Giant Cell Eosinophilic Pneumonia Lipid Pneumonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shapiro, S., Slone, D., Lewis, G.P. & Jick, H. Fatal drug reactions among medical inpatients. Journal American Medical Association, 1971, 216, 467–472.CrossRefGoogle Scholar
  2. 2.
    Friedman, G.D., Collen, M. F., Harris, L. E., van Brunt, E. E. & Davis, L. S. Experience in monitoring drug reactions in outpatients. Journal American Medical Association, 1971, 217, 567–572.CrossRefGoogle Scholar
  3. 3.
    Hutchinson, T. A., Leventhal, J. M., Kramer, M. S., Karch, F. E., Lipman, A. G. & Feinstein, A. R, An algorithm for the operational assessment of adverse drug reactions. II Demonstration of reproducibility and validity. Journal American Medical Association, 1979, 242, 633–638.CrossRefGoogle Scholar
  4. 4.
    Rosenheim, M. L., Editor. Sensitivity reactions to drugs. (Co-ed ited by Moulton, R.) Blackwell, Oxford, p.1.1958.Google Scholar
  5. 5.
    Crofton, J. W., Livingstone, J. L., Oswald, N. C. & Roberts, A. T. M. Pulmonary oesinophilia. Thorax, 1972, 7, 1–35.CrossRefGoogle Scholar
  6. 6.
    Taskinen, E., Tukiainen, P. & Sovijarvi, A. R. A. Nitrofurantoin-induced alterations in pulmonary tissue. Acta path. microbiol. Scand. Sect. A. 1977, 85, 713–720.Google Scholar
  7. 7.
    Fiegenberg, D. S., Weiss, H. & Kirshman, H. Migratory pneumonia with eosinophilia. Arch. Intern. Med. 1967, 120, 85–88.CrossRefGoogle Scholar
  8. 8.
    Katzenstein, A-L. A., Bloor, C. M. & Leibow, A. A. Diffuse alveolar damage — The role of oxygen, shock, and related factors. Amer. J. Path, 1976, 85, 210–224.Google Scholar
  9. 9.
    Heard, B. E. & Cooke, R. A. Busulphan lung. Thorax, 1968, 23, 187–193.CrossRefGoogle Scholar
  10. 10.
    Vijeyaratnam, G. S. & Corrin, B. Fine structural alterations in the lungs of iprindoletreated rats. J. Path, 1974, 114, 233–239.CrossRefGoogle Scholar
  11. 11.
    Heath, D., Smith, P. & Hasleton, P. S. Effects of chlorphentermine on the rat lung. Thorax, 1973, 28, 551–558.CrossRefGoogle Scholar
  12. 12.
    Heppleston, A. G., Fletcher, K., Wyatt, I. Changes in the composition of the lung lipids and the “turnover” of dipalmitoyl lecithin in experimental alveolar lipoproteinosis induced by inhaled quartz. Brit. J. exp. Path., 1974, 384–395.Google Scholar
  13. 13.
    Salm, R. & Hughes, E. W. A case of chronic paraf f in pneumonitis. Thorax, 1970, 25, 762–768.CrossRefGoogle Scholar
  14. 14.
    Kay, J. M., Smith, P. & Heath, D. Aminorex and the pulmonary circulation. Thorax, 1971, 26, 262–270.CrossRefGoogle Scholar
  15. 15.
    Kay, J. M. & Heath, D. Observations on the pulmonary arteries and heart weight of rats fed on crotalaria spectabilis s eed s. J. Path. Bact. 1966, 92, 385–394.CrossRefGoogle Scholar
  16. 16.
    Douglas, J. G., Munro, J. F., Kitchin, A. H., Muir, A. L. & Proudfoot, A. T. Pulmonary hypertension and Fenfluramine. Brit. Med. J., 1981, 283, 881–883.CrossRefGoogle Scholar
  17. 17.
    Waller, B. F., Brownlee, W. J. & Roberts, W. C. Self-induced pulmonary granulomatosis. A consequence of intravenous injection of drugs intended for oral use. Chest, 1980, 78, 90–94.CrossRefGoogle Scholar
  18. 18.
    Weber, W. R., Askin, F. B. & Dehner, L. P. Lung biopsy in pneumocystis carinii pneumonia. Am. J. Clin. Pathol. 1977, 67, 11–19.Google Scholar
  19. 19.
    Askin, F. B. & Katzenstein, A-L: A. Pneumocystis infection masquerading as diffuse alveolar damage. Chest, 1981, 79, 420–422.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • B. Corrin
    • 1
  1. 1.Cardiothoracic InstituteBrompton HospitalLondonUK

Personalised recommendations